Reported 1 day ago
H.C. Wainwright has raised its price target for Summit Therapeutics Inc. (NASDAQ:SMMT) from $44 to $50, maintaining a Buy rating. The firm highlighted the positive results from Akeso’s HARMONi-A study, indicating that their drug ivonescimab outperforms Keytruda. Summit Therapeutics focuses on developing therapies for serious medical needs, particularly Clostridioides Difficile Infection (CDI).
Source: YAHOO